COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
(New York, USA) DelveInsight’s, “Focal Segmental Glomerulosclerosis – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in Focal Segmental Glomerulosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To know more about Focal Segmental Glomerulosclerosis pipeline @ Focal Segmental Glomerulosclerosis Pipeline Assessment
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed. It typically presents with nephrotic syndrome with characterized proteinuria and obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts. However, the capillary injury does not occupy the entire glomerulus.
Some of the key companies in the Focal Segmental Glomerulosclerosis (FSGS) Market include:
Request for Sample Pages @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight
Focal Segmental Glomerulosclerosis Pipeline Analysis
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample Pages @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight
Emerging Focal Segmental Glomerulosclerosis Drugs
DMX-200: Dimerix Bioscience
DMX-200 is a chemokine receptor (CCR2) blocker and is administered to patients taking an angiotensin II type I (AT1) receptor blocker (ARB), which is the standard of care treatment for focal segmental glomerulosclerosis. DMX-200 has been granted patents in various territories until 2032 and has also been granted Orphan Drug Designation by the FDA and EMA.
Sparsentan: Travere Therapeutics
Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Currently, Sparsentan is in Phase III development for the treatment of focal segmental glomerulosclerosis (FSGS).
Request for Sample Pages @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight
Focal Segmental Glomerulosclerosis Therapeutics Landscape
The available therapeutics treatment options in the Focal Segmental Glomerulosclerosis (FSGS) landscape aims to reduce complications and protect from further kidney damage. Few companies are performing clinical trials to develop cell therapies and receptor modulators for the treatment of FSGS.
Focal Segmental Glomerulosclerosis (FSGS) Therapies covered in the report include:
Request for Sample Pages @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight
Table of Content
Latest Reports By DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting